Contract facts
FederalNo full NAICS 334516 intel page yet. Browse NAICS intelligence
EXERCISE OY I BY EXTENDING THE POP 13 MAR 2022-14 MAR 2023. FUND CLINS 1001, 1002 AND 1003. AS A RESULT OF THIS MODIFICATION, THE TOTAL VALUE OF THIS CONTRACT IS INCREASED BY $341,648.43, FROM $341,648.46 TO $683,296.89 is a federal award for Fa2860 316 Cons Pk held by Roche Diagnostics Corp. Estimated value $1.9M ($1.5M obligated). Current period of performance ends Mar 12, 2026 (potential Sep 12, 2026). Last award drew 1 bidder. Place of performance: ANDREWS AFB MD. Related solicitation FA286021Q0015.
EXERCISE OY I BY EXTENDING THE POP 13 MAR 2022-14 MAR 2023. FUND CLINS 1001, 1002 AND 1003. AS A RESULT OF THIS MODIFICATION, THE TOTAL VALUE OF THIS CONTRACT IS INCREASED BY $341,648.43, FROM $341,648.46 TO $683,296.89
Recompete timing
PublicCurrent PoP ended Mar 12, 2026 (162 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordRoche Diagnostics Corp — $245.9M obligated across 1,391 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract FA286021F0019?
FA286021F0019 (Exercise OY i BY extending the) is a Fa2860 316 Cons Pk award with a potential value of $1.9M, currently held by Roche Diagnostics Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is FA2860-21-F-0019?
FA2860-21-F-0019 is the dashed form of PIID FA286021F0019 (Exercise OY i BY extending the), held by Roche Diagnostics Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded FA286021F0019?
Fa2860 316 Cons Pk awarded FA286021F0019 to Roche Diagnostics Corp (potential $1.9M).
Who is the incumbent on FA286021F0019?
Roche Diagnostics Corp is the incumbent with $245.9M across 1391 related awards in SCOUT’s public footprint. The current period of performance ends Mar 12, 2026.
When does Roche Diagnostics Corp’s FA286021F0019 come up for recompete?
SCOUT tracks a period-of-performance end of Mar 12, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.